Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization
- PMID: 39954328
- PMCID: PMC11872481
- DOI: 10.1016/j.htct.2025.103738
Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization
Abstract
Introduction: Granulocyte colony-stimulating factor (G-CSF) is the most prevalently used growth factor for peripheral blood hematopoietic stem cell (HSC) mobilization. Most centers split the granulocyte colony-stimulating factor in two daily doses, whereas some centers administer one dose per day. This study aims to investigate the effect of the filgrastim dosing schedule on the quantity of hematopoietic stem cells collected after mobilization in healthy donors.
Methods: A total of 251 healthy donors mobilized in our center were included in the study. Mobilization was either once a day (filgrastim 1 × 10 mg/kg/day) or twice a day (filgrastim 2 × 5 mg/kg/day).
Results: White blood cell and peripheral CD34+ cell numbers were significantly higher in the Twice-a-day Group on the fifth day compared to the Once-a-day Group. No statistically significant difference was shown between the two groups regarding the number of CD34+ cells collected on the first apheresis day or the number of apheresis procedures needed to achieve the targeted number of CD34+ cells.
Conclusion: This study revealed that one daily dose of 10 mg/kg filgrastim is as effective as administering the same dose split on two days for an adequate amount of CD34+ cells in healthy donors.
Keywords: Filgrastim; G-CSF; Hematopoietic stem cell mobilization; Posology.
Copyright © 2025 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.
Conflict of interest statement
Conflicts of interest The authors declared no potential conflicts of interest concerning the research, authorship, and/or publication of this article.
Similar articles
-
High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.J Clin Oncol. 1999 Jul;17(7):2160-72. doi: 10.1200/JCO.1999.17.7.2160. J Clin Oncol. 1999. PMID: 10561272
-
Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.Ann Hematol. 2017 Oct;96(10):1735-1739. doi: 10.1007/s00277-017-3060-4. Epub 2017 Aug 11. Ann Hematol. 2017. PMID: 28801752 Free PMC article. Clinical Trial.
-
Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells.Transfusion. 1996 Jul;36(7):601-10. doi: 10.1046/j.1537-2995.1996.36796323059.x. Transfusion. 1996. PMID: 8701455
-
Optimizing Granulocyte-Colony Stimulating Factor Dosing Scheme in Healthy Stem Cell Donors for Allogenic Transplantation: A Retrospective Cohort Study of Single Dose vs. Split Dose.Cureus. 2024 Dec 29;16(12):e76553. doi: 10.7759/cureus.76553. eCollection 2024 Dec. Cureus. 2024. PMID: 39877775 Free PMC article.
-
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.Clin Ther. 2010 May;32(5):821-43. doi: 10.1016/j.clinthera.2010.05.007. Clin Ther. 2010. PMID: 20685493 Review.
References
-
- Dreger P., Haferlach T., Eckstein V., Jacobs S., Suttorp M., Löffler H., et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994;87:609–613. - PubMed
-
- Bensinger W.I., Weaver C.H., Appelbaum F.R., Rowley S., Demirer T., Sanders J., et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood. 1995;85:1655–1658. - PubMed
-
- Horowitz M., Confer L. American Soc of Hematol Program Book; 2005. Evaluation of Hematopoietic Stem Cell Donors; pp. 469–475. - PubMed
-
- Stiff P.J. Management strategies for the hard-to-mobilize patient. Bone Marrow Transpl. 1999;23(Suppl. 2):29–33. - PubMed
-
- Takeyama K., Ohto H. Peripheral stem cell mobilization. Transfus Apher Sci. 2004;31(3):233–243. - PubMed
LinkOut - more resources
Full Text Sources